AmplifybioHorizontal WhiteV1.RGB

Since spinning out of Battelle, AmplifyBio has amplified both staff and its research mission

February 13, 2023 09:00 ET | Author: Carrie Ghose, Columbus Business Journal

We’re absolutely thrilled that our recent growth to over 300 employees was covered by the Columbus Business Journal, and we can’t wait to continue growing our capabilities to serve the needs of advanced therapeutic development.

Read the article here.

AmplifyBio has seen a surge in clients looking to bring regenerative medicine to market, adding 28 new clients in the past year, and it’s also building a lab in New Albany with plans for more high-paying jobs, expected to open later this year. The organization has since broadened its focus to advanced therapies, including biologically-based treatments such as mRNA vaccines. Its recent growth means the company now combines deep scientific experience with a nimble start-up structure, hoping to use its capabilities to help clients find the best formulations and production methods to produce therapy at a large scale cost-effectively.

Read the article from Columbus Business Journal here.

About AmplifyBio

AmplifyBio is a leading preclinical CRO focused on toxicology, safety and pharmacology testing, as well as advance therapeutics for the betterment of human health. Spun out of Battelle in May of 2021, AmplifyBio’s mission is to continue to provide exceptional CRO study services in an agile environment suited to commercial goals and expand analytic capabilities to serve the dynamic needs of advanced therapy development. Clients of AmplifyBio enjoy the peace of mind that comes from decades of experience in GLP and non-GLP study design and execution, combined with rapid investment in technology, expertise, and infrastructure that together provide the critical components of a reliable, preclinical partnership. 

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest